P4 Enhances their NGS capabilities to offer Precision Medicine to their patients
P4 Diagnostix®, a network of nationally recognized laboratories (“P4”), will be partnering with Pierian, a global leader in advanced clinical genomics technology and services, to launch somatic testing for prostate cancer patients.
Using the Illumina TruSight Oncology 500 cancer panel, P4 and Pierian will expand P4’s Urology NGS services to incorporate somatic testing which will complement P4’s current germline testing product, UroSeq®. The testing will launch at P4’s Indianapolis laboratory.
“Precision medicine is a game-changer for patients diagnosed with metastatic prostate cancer,” stated Gay Bush, PhD, Director of Operations for P4 Indianapolis. “This post biopsy information helps physicians gain a deeper understanding of available therapy options, creating improved clinical outcomes on this patient population.”
Dr. Bush added, “The interest in NGS testing has grown substantially for urologists so the addition of somatic testing was a natural evolution for P4 and our clients who are already using UroSeq for germline testing.”
“Our partnership with P4 is a strong demonstration of the importance of Precision Medicine in a growing number of clinical settings” said Lindsay Mateo, Chief Business Officer at Pierian. “We are proud to be partnered with such a leading-edge organization and confident that together we will increase access to genomics and continue to positively impact patient care.”
Since 2020, P4 has worked with urology practices nationwide to incorporate germline testing into their post-prostate biopsy workflow. P4 provides consulting and other pathology lab services to many of the Large Urology Group Practice Association (LUGPA) organizations.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
